A post hoc analysis of the DIVERSITY-CVR trial tests whether baseline ALT predicts differential HbA1c and time-in-range responses to dapagliflozin versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
An early-phase trial of the GLP-1/FGF21 dual agonist HEC88473 reported dose-proportional liver fat reduction and improved glycaemic control over 5 weeks in patients with MASLD and type 2 diabetes. PICO summary and expert commentary.
A 12-week four-arm randomised trial in 36 male recreational athletes found that combined diet plus exercise improved body composition and glycaemic markers, with small effect sizes. PICO summary and expert commentary.
A secondary analysis of the VA NEPHRON-D cohort found that higher baseline urinary EGF and uromodulin were independently associated with a lower risk of diabetic kidney disease progression. PICO summary and expert commentary.
Once-weekly fixed-dose insulin efsitora was noninferior to once-daily glargine for HbA1c reduction over 52 weeks in insulin-naive type 2 diabetes, with less hypoglycaemia. PICO summary and expert commentary.
A 16-week randomized trial found combined training lowered GLP-1 and amylin and raised DPP-4 in adults with type 2 diabetes and overweight, without a demonstrated glycaemic benefit. PICO summary and expert commentary.
A randomized trial testing whether a patient previsit activation handout, added to physician academic detailing, increases diabetes medication deprescribing in adults 75 and older. PICO summary and expert commentary.
An exploratory open-label RCT found imeglimin and metformin lowered HbA1c similarly, but only imeglimin raised insulin and GIP secretion. PICO summary and expert commentary.
Replacing mealtime insulin with weekly semaglutide missed its primary glycaemic target (90% vs 75%, p=0.18) but cut weight and insulin dose in this small open-label trial. PICO summary and expert commentary.
A prespecified STRIDE subgroup analysis examined whether once-weekly semaglutide 1.0 mg improves walking distance consistently across diabetes characteristics in 792 adults with symptomatic PAD and type 2 diabetes. PICO summary and expert commentary.